Altay Therapeutics

Executive Summary

Altay Therapeutics is a private biotech company based in San Diego, founded in 2020, pioneering the first oral drug for Facioscapulohumeral muscular dystrophy (FSHD) and advancing small-molecule cancer treatments. FSHD is a rare, progressive genetic muscle disorder with no approved therapies, representing a high unmet medical need. Altay's lead candidate targets the underlying molecular pathology, offering potential disease modification with oral administration. The company is currently in Phase 1/2 clinical development, with early data expected to demonstrate safety and preliminary efficacy. In oncology, Altay is developing novel small molecules aimed at key oncogenic pathways, leveraging its expertise in targeted therapeutics. While specific pipeline details remain undisclosed, the dual focus on rare disease and oncology positions Altay for multiple value inflection points. The company's platform could yield additional indications and partnerships, driven by its innovative chemistry and biology.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 FSHD clinical data readout35% success
• Q2 2027IND filing for lead oncology candidate50% success
• H1 2027Strategic partnership or licensing deal for FSHD program40% success